126 related articles for article (PubMed ID: 38305380)
1. A monofunctional Pt(II) complex combats triple negative breast cancer by triggering lysosome-dependent cell death.
Shen X; Peng Y; Yang Z; Li R; Zhou H; Ye X; Han Z; Shi X
Dalton Trans; 2024 Feb; 53(8):3808-3817. PubMed ID: 38305380
[TBL] [Abstract][Full Text] [Related]
2. Anti-cancer characteristics and ototoxicity of platinum(II) amine complexes with only one leaving ligand.
Monroe JD; Hruska HL; Ruggles HK; Williams KM; Smith ME
PLoS One; 2018; 13(3):e0192505. PubMed ID: 29513752
[TBL] [Abstract][Full Text] [Related]
3. A novel star-shaped trinuclear platinum(II) complex based on a 1,3,5-triazine core displaying potent antiproliferative activity against TNBC by the mitochondrial injury and DNA damage mechanism.
Wu Y; Zhao D; Shang J; Huang W; Chen Z
Dalton Trans; 2022 Jul; 51(29):10930-10942. PubMed ID: 35731536
[TBL] [Abstract][Full Text] [Related]
4. Elucidating the Multimodal Anticancer Mechanism of an Organometallic Terpyridine Platinum(II) N-Heterocyclic Carbene Complex against Triple-Negative Breast Cancer In Vitro and In Vivo.
Zhang JJ; Xu QJ; Schmidt C; Maaty MAAE; Song J; Yu C; Zhou J; Han K; Sun H; Casini A; Ott I; Wölfl S
J Med Chem; 2023 Mar; 66(6):3995-4008. PubMed ID: 36898000
[TBL] [Abstract][Full Text] [Related]
5. Identification of a luminescent platinum(II) complex with BODIPY derivative as novel photodynamic therapy agent for triple negative breast cancer cells.
Wang Y; Wang S; Wang Q; Tang W; Lin L; Zhang T; Hu M; Wang X
J Inorg Biochem; 2023 May; 242():112160. PubMed ID: 36791603
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of antitumor azolato-bridged dinuclear platinum(ii) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles.
Komeda S; Takayama H; Suzuki T; Odani A; Yamori T; Chikuma M
Metallomics; 2013 May; 5(5):461-8. PubMed ID: 23608770
[TBL] [Abstract][Full Text] [Related]
7. A New Approach to Sensitize Antitumor Monofunctional Platinum(II) Complexes via Short Time Photo-Irradiation.
Xue X; Zhu C; Chen H; Bai Y; Shi X; Jiao Y; Chen Z; Miao Y; He W; Guo Z
Inorg Chem; 2017 Apr; 56(7):3754-3762. PubMed ID: 28080031
[TBL] [Abstract][Full Text] [Related]
8. APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC.
Malfatti MC; Gerratana L; Dalla E; Isola M; Damante G; Di Loreto C; Puglisi F; Tell G
J Exp Clin Cancer Res; 2019 Jul; 38(1):309. PubMed ID: 31307523
[TBL] [Abstract][Full Text] [Related]
9. Do platinum salts fit all triple negative breast cancers?
Gerratana L; Fanotto V; Pelizzari G; Agostinetto E; Puglisi F
Cancer Treat Rev; 2016 Jul; 48():34-41. PubMed ID: 27343437
[TBL] [Abstract][Full Text] [Related]
10. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
[TBL] [Abstract][Full Text] [Related]
11. ONS-donor ligand based Pt(II) complexes display extremely high anticancer potency through autophagic cell death pathway.
Rahman FU; Ali A; Duong HQ; Khan IU; Bhatti MZ; Li ZT; Wang H; Zhang DW
Eur J Med Chem; 2019 Feb; 164():546-561. PubMed ID: 30622026
[TBL] [Abstract][Full Text] [Related]
12. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
13. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
Pandy JGP; Balolong-Garcia JC; Cruz-Ordinario MVB; Que FVF
BMC Cancer; 2019 Nov; 19(1):1065. PubMed ID: 31703646
[TBL] [Abstract][Full Text] [Related]
14. Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways.
Bai X; Ali A; Lv Z; Wang N; Zhao X; Hao H; Zhang Y; Rahman FU
Eur J Med Chem; 2021 Nov; 224():113689. PubMed ID: 34293698
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers.
Serebryanskaya TV; Yung T; Bogdanov AA; Shchebet A; Johnsen SA; Lyakhov AS; Ivashkevich LS; Ibrahimava ZA; Garbuzenco TS; Kolesnikova TS; Melnova NI; Gaponik PN; Ivashkevich OA
J Inorg Biochem; 2013 Mar; 120():44-53. PubMed ID: 23305964
[TBL] [Abstract][Full Text] [Related]
16. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-delivered miriplatin ultrasmall dots suppress triple negative breast cancer lung metastasis by targeting circulating tumor cells.
Li Y; Qian D; Lin HP; Xie J; Yang P; Maddy D; Xiao Y; Huang X; Wang Z; Yang C
J Control Release; 2021 Jan; 329():833-846. PubMed ID: 33045314
[TBL] [Abstract][Full Text] [Related]
18. A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis.
Guo Y; Zhang S; Yuan H; Song D; Jin S; Guo Z; Wang X
Dalton Trans; 2019 Mar; 48(11):3571-3575. PubMed ID: 30793153
[TBL] [Abstract][Full Text] [Related]
19. Monofunctional platinum(II) complexes with potent tumor cell growth inhibitory activity: the effect of a hydrogen-bond donor/acceptor N-heterocyclic ligand.
Margiotta N; Savino S; Gandin V; Marzano C; Natile G
ChemMedChem; 2014 Jun; 9(6):1161-8. PubMed ID: 24799414
[TBL] [Abstract][Full Text] [Related]
20. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells.
Ding Y; Chen X; Liu C; Ge W; Wang Q; Hao X; Wang M; Chen Y; Zhang Q
J Hematol Oncol; 2021 Jan; 14(1):19. PubMed ID: 33472669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
